![Paolo Tarantino: We just see the tip of the iceberg of how ADCs work](https://oncodaily.com/pub/uploads/2024/07/N7-QBrt1_400x400-e1721483692691.png)
Paolo Tarantino: We just see the tip of the iceberg of how ADCs work
Paolo Tarantino shared on X: .
“On my way to NY to review the present and future of ADCs at IBC East.What an impact these drug have had in the treatment of breast cancer!
Yet, so many open questions remain.
We just see the tip of the iceberg of how ADCs work.
Underneath lies an ocean of opportunities.”
Source: Paolo Tarantino/X
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.
With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.